123 related articles for article (PubMed ID: 2104808)
1. Long-term suppression of ovarian function by a luteinizing-hormone releasing hormone agonist implant in patients with endometriosis.
Fraser HM; Sandow J; Cowen GM; Lumsden MA; Haining R; Smith SK
Fertil Steril; 1990 Jan; 53(1):61-8. PubMed ID: 2104808
[TBL] [Abstract][Full Text] [Related]
2. GnRH agonist administration in polycystic ovary syndrome.
Buckler HM; Phillips SE; Kovacs GT; Burger HG; Healy DL
Clin Endocrinol (Oxf); 1989 Aug; 31(2):151-65. PubMed ID: 2514053
[TBL] [Abstract][Full Text] [Related]
3. Long-acting gonadotrophin releasing hormone agonist implant causes variable duration of suppression of ovarian steroid and inhibin secretion.
Fraser HM; Haining R; Cowen GM; Sandow J; Smith KB; Smith SK
Clin Endocrinol (Oxf); 1992 Jan; 36(1):97-104. PubMed ID: 1559303
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
5. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis.
Lemay A; Maheux R; Faure N; Jean C; Fazekas AT
Fertil Steril; 1984 Jun; 41(6):863-71. PubMed ID: 6427019
[TBL] [Abstract][Full Text] [Related]
6. Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.
Lemay A; Quesnel G
Fertil Steril; 1982 Sep; 38(3):376-9. PubMed ID: 6214431
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis.
Lemay A; Maheux R; Huot C; Blanchet J; Faure N
Am J Obstet Gynecol; 1988 Feb; 158(2):233-6. PubMed ID: 3124618
[TBL] [Abstract][Full Text] [Related]
8. Luteinizing hormone releasing hormone agonist for contraception in breast feeding women.
Fraser HM; Dewart PJ; Smith SK; Cowen GM; Sandow J; McNeilly AS
J Clin Endocrinol Metab; 1989 Nov; 69(5):996-1002. PubMed ID: 2507572
[TBL] [Abstract][Full Text] [Related]
9. Suppression in the secretion of follicle-stimulating hormone and luteinizing hormone, and ovarian follicle development in heifers continuously infused with a gonadotropin-releasing hormone agonist.
Gong JG; Campbell BK; Bramley TA; Gutierrez CG; Peters AR; Webb R
Biol Reprod; 1996 Jul; 55(1):68-74. PubMed ID: 8793060
[TBL] [Abstract][Full Text] [Related]
10. Prevention of follicular maturation in endometriosis by subcutaneous infusion of luteinizing hormone-releasing hormone agonist started in the luteal phase.
Lemay A; Sandow J; Bureau M; Maheux R; Fontaine JY; Mérat P
Fertil Steril; 1988 Mar; 49(3):410-7. PubMed ID: 3125068
[TBL] [Abstract][Full Text] [Related]
11. Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N; Bastide A
Fertil Steril; 1987 Jan; 47(1):60-6. PubMed ID: 2947818
[TBL] [Abstract][Full Text] [Related]
12. [Successful treatment of endometriosis in women with continuous subcutaneous infusion of gonadotropin-releasing hormone agonist (GnRH-A)].
Masaoka K; Kitazawa M; Kumasaka T
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Apr; 41(4):405-11. PubMed ID: 2501437
[TBL] [Abstract][Full Text] [Related]
13. Rapid inhibitory effects of an LHRH agonist implant on the oestrogen-induced LH surge and the induction of a defective luteal phase after an agonist-induced ovulation in the macaque.
Fraser HM; Lunn SF
Hum Reprod; 1989 Jul; 4(5):506-12. PubMed ID: 2507574
[TBL] [Abstract][Full Text] [Related]
14. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N
J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
[TBL] [Abstract][Full Text] [Related]
15. Suppression of follicular maturation by infusion of a luteinizing hormone-releasing hormone agonist starting during the late luteal phase in the stumptailed macaque monkey.
Fraser HM; Sandow J
J Clin Endocrinol Metab; 1985 Mar; 60(3):579-84. PubMed ID: 3919049
[TBL] [Abstract][Full Text] [Related]
16. Atypical response to luteinizing hormone-releasing hormone (LH-RH) agonist (suprefact nasal) in induction of ovulation in in vitro fertilization (IVF).
Lessing JB; Cohen JR; Yovel I; Amit A; David MP; Peyser MR
J In Vitro Fert Embryo Transf; 1991 Dec; 8(6):314-6. PubMed ID: 1770271
[TBL] [Abstract][Full Text] [Related]
17. Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting luteinizing hormone releasing hormone agonist analogue.
West CP; Baird DT
Clin Endocrinol (Oxf); 1987 Feb; 26(2):213-20. PubMed ID: 2959405
[TBL] [Abstract][Full Text] [Related]
18. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
Behre HM; Nashan D; Hubert W; Nieschlag E
J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
[TBL] [Abstract][Full Text] [Related]
19. Gonadotropins and estradiol responses to single intranasal or subcutaneous administration of a luteinizing hormone-releasing hormone agonist in the early follicular phase.
Lemay A; Metha AE; Tolis G; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1983 May; 39(5):668-73. PubMed ID: 6404661
[TBL] [Abstract][Full Text] [Related]
20. Studies on GnRH agonist suppression of estrogen production in patients with endometriosis.
Ohtsuka S; Terakawa N; Shimizu I; Sakata M; Mizutani T; Miyake A; Tanizawa O; Aono T
Endocrinol Jpn; 1989 Aug; 36(4):611-9. PubMed ID: 2510993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
